Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.66 Analyst target: $17.50 Upside: 2548.31%
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.